FAHIM RAAFAT E F 4
4 · NABI BIOPHARMACEUTICALS · Filed Apr 5, 2011
Insider Transaction Report
Form 4
FAHIM RAAFAT E F
DirectorPresident, CEO and CFO
Transactions
- Award
Common Stock
2011-04-01+50,000→ 386,756.941 total - Other
Common Stock
2010-05-31$4.20/sh+3,096$13,003→ 333,733.941 total - Sale
Common Stock
2011-04-05$5.76/sh−13,283$76,458→ 373,473.941 total - Award
Stock Option (right to buy)
2011-04-01+150,000→ 150,000 totalExercise: $5.81Exp: 2018-04-01→ Common Stock (150,000 underlying) - Other
Common Stock
2010-11-30$4.30/sh+3,023$12,999→ 336,756.941 total
Footnotes (4)
- [F1]Voluntarily reported acquisition under the Issuer's 2000 Employee Stock Purchase Plan, which is an exempt transaction pursuant to Rule 16b-3.
- [F2]Restricted Stock which vests in four equal annual installments beginning on April 1, 2012.
- [F3]This disposition was made to fund the Reporting Person's tax obligation arising from the vesting of restricted stock.
- [F4]This Option will become exercisable in four equal annual installments beginning on April 1, 2012.